23
Mar
2022

LifeMine Snags GSK Deal and $175m to Drive Fungus-Based Drug Discovery

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

Fungus-Based Startup, LifeMine, Fetches $50M; Arsenal Attracts BMS Cell Therapy